Physicians wishing to request RUCONEST through the HAEi GAP program should contact the Clinigen customer services team at firstname.lastname@example.org or on 0044 1283 494340.
"HAEi is committed to securing access to HAE medications for patients across the globe," said Anthony J.
Simon Estcourt, Managing Director, Managed Access, Clinigen Group said: "We are very pleased to work with Pharming to help HAEi realize their mission to ensure that sufferers of hereditary angioedema worldwide can access this effective and potentially life-saving treatment.
Castaldo, President of HAEi. “We are extremely proud to have established HAEi GAP with our current partners and will continue to work with other manufacturers with the hope of expanding the program in the future.”
We look forward to working with both HAEi and Pharming on this unique project.”
Sijmen de Vries, CEO, Pharming said: “We are delighted to be the first partners of HAEi and to initiate this program by providing access to RUCONEST, a recombinant human C1- inhibitor, approved by EMA and FDA for the treatment of acute attacks of HAE in patients.